



## Genetic Analysis AS: Mandatory notification of trade

**OSLO, NORWAY - 15 September 2021: Genetic Analysis AS (“GA” or “the Company”) announce that members of the Board and management have been allocated GEAN-shares and warrants of series TO 1 and TO 2 in connection with their IPO subscription.**

**Kathryn M. Baker**, Chairperson of the Board in Genetic Analysis AS, has through the fully owned company Lakeside AS today subscribed for and been allocated 64,100 GEAN-shares at a price of 7.80 NOK per share and in addition free of charge 38,460 subscription rights of series TO 1 and 44,870 subscription rights of series TO 2. Kathryn M. Baker including controlled company owns 64,100 shares and 83,330 subscription rights following the transaction.

**Camilla Huse Bondesson**, Board member in Genetic Analysis AS, has today subscribed for and been allocated 38,460 GEAN-shares at a price of 7.80 NOK per share and in addition free of charge 23,076 subscription rights of series TO 1 and 26,922 subscription rights of series TO 2. Camilla Huse Bondesson owns 38,460 shares and 49,998 subscription rights following the transaction.

**Ronny Hermansen**, CEO in Genetic Analysis AS, has through the fully owned company InVitroDia AS today subscribed for and been allocated 38,460 GEAN-shares at a price of 7.80 NOK per share and in addition free of charge 23,076 subscription rights of series TO 1 and 26,922 subscription rights of series TO 2. Ronny Hermansen including controlled company owns 154,552 shares and 49,998 subscription rights following the transaction.

**Christina Casén**, SVP Medical & Clinical Affairs in Genetic Analysis AS, has today subscribed for and been allocated 38,460 GEAN-shares at a price of 7.80 NOK per share and in addition free of charge 23,076 subscription rights of series TO 1 and 26,922 subscription rights of series TO 2. Christina Casén owns 87,072 shares and 49,998 subscription rights following the transaction.

**Anita Patel Jusnes**, CCO in Genetic Analysis AS, has today subscribed for and been allocated 38,460 GEAN-shares at a price of 7.80 NOK per share and in addition free of charge 23,076 subscription rights of series TO 1 and 26,922 subscription rights of series TO 2. Anita Patel Jusnes owns 38,460 shares and 49,998 subscription rights following the transaction.

**Kari Furu**, CTO in Genetic Analysis AS, has today subscribed for and been allocated 10,000 GEAN-shares at a price of 7.80 NOK per share and in addition free of charge 6,000 subscription rights of series TO 1 and 7,000 subscription rights of series TO 2. Kari Furu owns 10,000 shares and 13,000 subscription rights following the transaction.

**Tore Grøttum**, IPO Project Manager in Genetic Analysis AS, has today subscribed for and been allocated 128,200 GEAN-shares at a price of 7.80 NOK per share and in addition free of charge 76,920 subscription rights of series TO 1 and 89,740 subscription rights of series TO 2. Tore Grøttum owns 238,514 shares and 166,660 subscription rights following the transaction.

**Eilert Aamodt**, CFO in Genetic Analysis AS, has through the fully owned company E. B. Aamodt AS today subscribed for and been allocated 38,460 GEAN-shares at a price of 7.80 NOK per share and in addition free of charge 23,076 subscription rights of series TO 1 and 26,922 subscription rights of series TO 2. Eilert Aamodt including controlled company owns 38,460 shares and 49,998 subscription rights following the transaction.

**For more information on Genetic Analysis AS, please contact:**

Ronny Hermansen, CEO

E-mail: [rh@genetic-analysis.com](mailto:rh@genetic-analysis.com)

**About Genetic Analysis AS**

Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 10 years of expertise in research and product development. The unique GA-map® platform is based on a pre-targeted multiplex approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need of further bioinformatics work. GA's vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA holds 22 highly qualified employees with relevant scientific backgrounds and with competence in bioinformatics, molecular biology, and bioengineering. [www.genetic-analysis.com](http://www.genetic-analysis.com)